Delivery Order SPE2DB20D2014-SPE2DB25FC96X
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100 count) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $27,735.62 and carries no set-aside designation. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $12,986.33 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500 count) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed price, competitively awarded delivery order represents a single pharmaceutical product shipment with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the...
- The Defense Logistics Agency awarded a delivery order valued at $33,203.38 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count units). This competitive, firm fixed-price delivery order was executed on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract does not carry a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $12,027.50 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count) on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and specifies performance at the contractor's facility in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication used to prevent organ...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of CellCept 500 mg tablets (100-count units) valued at $7,015.33. This firm fixed-price delivery order, with an ultimate completion date of August 5, 2025, represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $35,063.75 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order under a larger contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order valued at $2,545.90 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg on September 3, 2025, with an ultimate completion date of September 4, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its Corporate Office division as part of ongoing...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for CellCept 500 mg tablets (100 count) valued at $1,283.84, with an award date of August 13, 2025, and ultimate completion by August 14, 2025. This firm fixed-price, non-set-aside delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle running through...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitively awarded delivery order (Contract No. 4568982464) by the Defense Logistics Agency on August 4, 2025, for the supply of CellCept 500 mg tablets in a quantity of 100 units. This firm fixed-price delivery order carries a ceiling value of $7,817.19 and is scheduled for ultimate completion by August 5, 2025. The contract carries no set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order valued at $9,024.78 to AmerisourceBergen Drug Corp for CellCept 500 mg tablets (100-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order represents a non-competitive set-aside and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication commonly used in military and...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC96XDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,717.35 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count) on September 10, 2025, with completion scheduled for September 11, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, which is also the location of AmerisourceBergen's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military and defense healthcare programs worldwide. CellCept, an immunosuppressant medication commonly used in transplant and autoimmune disease management, represents one of many specialty pharmaceutical products delivered under this strategic contract with the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.7k | 9/10/25 |